Frailty in Vasculitis

Sparks editorial -- RA pathogenesis has been linked to pollution, Lung Dz, smoking, silica dust, asbestos, textile dust

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Sparks editorial -- RA pathogenesis has been linked to pollution, Lung Dz, smoking, silica dust, asbestos, textile dust, brick/concrete laying, pesticides, military burn pits - some w/ strong associ w/ HLA-SE and ACPA, but not ACPA-negative RA https://t.co/ZStmF8MeLD https://t.co/xQxJ74aQ81
Links
https://bit.ly/3Phy4G7

SLE: Variability in Racial Disparities in Pregnancy Outcomes Significant disparities exist in pregnancy outcomes in wo

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
SLE: Variability in Racial Disparities in Pregnancy Outcomes Significant disparities exist in pregnancy outcomes in women with SLE, w/previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women w/SLE. https://t.co/1PrJYpMcHx https://t.co/YN7K0Gf5Jl
Links
https://bit.ly/3HjoHDU

The Top 10 Research Priorities in Psoriatic Arthritis A survey of 317 carers and clinicians focused on psoriatic arthr

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
The Top 10 Research Priorities in Psoriatic Arthritis A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA). https://t.co/zfivHvtLX9 https://t.co/LZsiE417w2
Links
https://bit.ly/3Y4BAYn

Systematic review comparing MIS-C and Kawasaki: 14 studies, 2928 pts; major differences- KD pts were younger; MIS-C had

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Systematic review comparing MIS-C and Kawasaki: 14 studies, 2928 pts; major differences- KD pts were younger; MIS-C had more Pulm, GI, Shock, more cardiac (LV, valvular pericarditis, myocarditis), but less coronary lesions & conjunctivitis https://t.co/bcCRh5HxL7 https://t.co/qLvfCYwx9u
Links
https://bit.ly/3HjBK8u

Comparing Biosimilar Growth in the US, Germany, and Switzerland The biosimilar landscape will change dramatically in 2

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Comparing Biosimilar Growth in the US, Germany, and Switzerland The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. https://t.co/LYcG0BNO6C https://t.co/V2m8HoIWLF
Links
https://bit.ly/3iNFzbS
7 December 2022
Xeljanz Cancer Risks Detailed

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL Surveillance trial was associated with incident cancers at a rate of 1.13 per 100 patient-years of treatment, compared with 0.77 per 100 patient-years with tumor necrosis factor (TNF) inhibitors, according to Jeffrey Curtis, MD, of the University of Alabama at Birmingham, and colleagues.

Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×